A recent publication in Cell Reports Medicine from researchers at the Washington University School of Medicine and the La Jolla Institute for Immunology presents a promising new strategy for H5N1 vaccination.

Auravax Therapeutics Inc. has received funding from the Gates Foundation to evaluate the efficacy of Nanosting-001 in validated swine models of influenza infection at Kansas State University College of Veterinary Medicine and The Pirbright Institute.

French vaccines specialist Osivax SAS has been awarded $19.5 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund work on its universal influenza A vaccine.

Compared to other forms of prevention, a unique issue for pandemic preparedness is that it is forever unclear what pathogen, exactly, the world needs to be prepared for. There are an estimated 300,000 viruses that infect mammals; add in birds, and the estimate grows to more than half a million. Some of those viruses are much greater threats than others.

Compared to other forms of prevention, a unique issue for pandemic preparedness is that it is forever unclear what pathogen, exactly, the world needs to be prepared for. There are an estimated 300,000 viruses that infect mammals; add in birds, and the estimate grows to more than half a million. Some of those viruses are much greater threats than others.

Compared to other forms of prevention, a unique issue for pandemic preparedness is that it is forever unclear what pathogen, exactly, the world needs to be prepared for. There are an estimated 300,000 viruses that infect mammals; add in birds, and the estimate grows to more than half a million. Some of those viruses are much greater threats than others.

Researchers from Diosynvax Ltd. presented data from a study that aimed to evaluate the efficacy of a pan-H5 vaccine designed using computational biology and being developed for protection against avian influenza.

Avian influenza viruses, particularly the H5 and H7 subtypes, can cause widespread outbreaks in birds and pose a significant zoonotic risk due to their potential to mutate and develop the ability for human-to-human transmission. Researchers from the University of Muenster described the preclinical efficacy of zapnometinib, a selective MEK1/2 inhibitor, against H5N1 clade 2.3.4.4b.

Scientists at the University of Pittsburgh have tested a broadly neutralizing antibody that binds the stem of a protein against H5N1 avian influenza, which prevented severe disease in nonhuman primates and was effective for at least 8 weeks. The scientists remark on the potential of the design developed by Astrazeneca plc against a possible outbreak of the influenza A virus.